Bacampicillin

Summary

Bacampicillin (CHEMBL1583) is an approved small-molecule prodrug (ATC J01CA06); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA06
• Indications: 2 conditions
• Chemistry: 465.5 Da · C21H27N3O7S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1583
Name	Bacampicillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	441397
ChEBI	CHEBI:2968
ATC	J01CA06
Molecular formula	C21H27N3O7S
Molecular weight	465.5
InChIKey	PFOLLRNADZZWEX-FFGRCDKISA-N

SMILES: CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C

IUPAC name: 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

ChEBI definition: A penicillanic acid ester that is the 1-ethoxycarbonyloxyethyl ester of ampicillin. It is a semi-synthetic, microbiologically inactive prodrug of ampicillin.

Pharmacological roles (ChEBI): prodrug.

Also known as: Bacampicilina, Bacampicillin, Bacampicilline, Penglobe, BACAMPICILLINE, BACAMPICILLIN, EPC-272, bacampicillin

Parent form; salt/anhydrous children: CHEMBL1200965

Patent coverage: 2,697 distinct patent families (10,410 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Kappa-type opioid receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).